Invisible in the Water, Devastating in the Lungs

What is it about?

It's a hot day as you get into a small lake to play with your kids. You all are jumping and swimming; it's indeed a nice day to be outside! Shortly after toweling off, you start feeling an itching sensation on your legs, and you immediately think about those mosquito bites from the previous evening; not even aware that Schistosoma cercariae were on the move, trying to reach your blood vessels to begin their journey through your entire cardiovascular system. At this point, you were not alone. Unfortunately, you joined more than 200 million people currently infected with this intravascular parasite worldwide. Of those, over one million may develop a serious lung disease called pulmonary arterial hypertension (PAH), a life-threatening condition for which there is currently no cure. This scenario raises a critical point: finding early diagnostic methods and novel treatments is essential not only for you but also for millions of people. In line with this need, the research team of Dr. Suellen D'Arc Oliveira at the University of Illinois Chicago, in collaboration with investigators from Stanford, Rush, Unifesp, UFRJ Universities, and Cleveland Clinic Foundation, identified two molecules that play critical roles in disease progression: a protein called c-IAP2 (inhibitor of apoptosis protein 2), which becomes abnormally reduced in affected lung vessels, and a receptor called P2X7, which becomes overactive when c-IAP2 levels fall. Together, the research team observed that these changes may fuel inflammation and contribute to the progressive thickening of lung blood vessel walls that defines PAH.

Featured Image

Photo by Robina Weermeijer on Unsplash

Photo by Robina Weermeijer on Unsplash

Why is it important?

These discoveries open two promising doors: 1) because c-IAP2 levels may begin to decline early in the disease process, measuring them may one day allow physicians to identify at-risk individuals before symptoms appear, and 2) since lung P2X7 receptors become overactive, drugs that selectively block them (already in development for other conditions) could potentially be repurposed in the future for schistosomiasis-associated PAH. Additionally, the findings revealed that changes in the microbiome leave lasting imprints on lung blood vessel cells, creating a biological "memory" that continues to drive disease, suggesting that effective treatment may need to address microbial signals alongside the vessels themselves. For the millions of people who wade into a lake on a warm afternoon, to play or to work, without knowing what is waiting in the water, that roadmap cannot come soon enough!

Perspectives